Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice

Bernardo Dell’Osso, Umberto Albert, Anna Rita Atti, Claudia Carmassi, Giuseppe Carrà, Fiammetta Cosci, Valeria Del Vecchio, Marco Di Nicola, Silvia Ferrari, Arianna Goracci, Felice Iasevoli, Mario Luciano, Giovanni Martinotti, Maria Giulia Nanni, Alessandra Nivoli, Federica Pinna, Nicola Poloni, Maurizio Pompili, Gaia Sampogna, Ilaria TarriconeSarah Tosato, Umberto Volpe, Andrea Fiorillo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

More than half a century after their discovery, benzodiazepines (BDZs) still represent one of the largest and most widely prescribed groups of psychotropic compounds, not only in clinical psychiatry but also in the entire medical field. Over the last two decades, however, there has been an increased focus on the development of antidepressants and antipsychotics on the part of the pharmaceutical industry, clinicians, and researchers, with a reduced interest in BDZs, in spite of their widespread clinical use. As a consequence, many psychiatric residents, medical students, nurses, and other mental health professionals might receive poor academic teaching and training regarding these agents, and have the false impression that BDZs represent an outdated chapter in clinical psychopharmacology. However, recent advances in the field, including findings concerning epidemiology, addiction risk, and drug interactions, as well as the introduction of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition with related diagnostic changes, strongly encourage an updated appraisal of the use of BDZs in clinical practice. During a recent thematic event convened with the aim of approaching this topic in a critical manner, a group of young Italian psychiatrists attempted to highlight possible flaws in current teaching pathways, identify the main clinical pros and cons regarding current use of BDZs in clinical practice, and provide an updated overview of their use across specific clinical areas and patient populations. The main results are presented and discussed in this review.

Original languageEnglish
Pages (from-to)1885-1909
Number of pages25
JournalNeuropsychiatric Disease and Treatment
Volume11
DOIs
Publication statusPublished - Jul 30 2015

Fingerprint

Benzodiazepines
Psychiatry
Education
Teaching
Psychopharmacology
Drug Industry
Medical Students
Drug Interactions
Diagnostic and Statistical Manual of Mental Disorders
Antidepressive Agents
Antipsychotic Agents
Mental Health
Epidemiology
Nurses
Research Personnel
Population

Keywords

  • Benzodiazepines
  • Psychiatric clinical practice
  • Risks and benefits
  • Teaching issues

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. / Dell’Osso, Bernardo; Albert, Umberto; Atti, Anna Rita; Carmassi, Claudia; Carrà, Giuseppe; Cosci, Fiammetta; Del Vecchio, Valeria; Di Nicola, Marco; Ferrari, Silvia; Goracci, Arianna; Iasevoli, Felice; Luciano, Mario; Martinotti, Giovanni; Nanni, Maria Giulia; Nivoli, Alessandra; Pinna, Federica; Poloni, Nicola; Pompili, Maurizio; Sampogna, Gaia; Tarricone, Ilaria; Tosato, Sarah; Volpe, Umberto; Fiorillo, Andrea.

In: Neuropsychiatric Disease and Treatment, Vol. 11, 30.07.2015, p. 1885-1909.

Research output: Contribution to journalArticle

Dell’Osso, B, Albert, U, Atti, AR, Carmassi, C, Carrà, G, Cosci, F, Del Vecchio, V, Di Nicola, M, Ferrari, S, Goracci, A, Iasevoli, F, Luciano, M, Martinotti, G, Nanni, MG, Nivoli, A, Pinna, F, Poloni, N, Pompili, M, Sampogna, G, Tarricone, I, Tosato, S, Volpe, U & Fiorillo, A 2015, 'Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice', Neuropsychiatric Disease and Treatment, vol. 11, pp. 1885-1909. https://doi.org/10.2147/NDT.S83130
Dell’Osso, Bernardo ; Albert, Umberto ; Atti, Anna Rita ; Carmassi, Claudia ; Carrà, Giuseppe ; Cosci, Fiammetta ; Del Vecchio, Valeria ; Di Nicola, Marco ; Ferrari, Silvia ; Goracci, Arianna ; Iasevoli, Felice ; Luciano, Mario ; Martinotti, Giovanni ; Nanni, Maria Giulia ; Nivoli, Alessandra ; Pinna, Federica ; Poloni, Nicola ; Pompili, Maurizio ; Sampogna, Gaia ; Tarricone, Ilaria ; Tosato, Sarah ; Volpe, Umberto ; Fiorillo, Andrea. / Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. In: Neuropsychiatric Disease and Treatment. 2015 ; Vol. 11. pp. 1885-1909.
@article{a92476a78934480588d829860b126407,
title = "Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice",
abstract = "More than half a century after their discovery, benzodiazepines (BDZs) still represent one of the largest and most widely prescribed groups of psychotropic compounds, not only in clinical psychiatry but also in the entire medical field. Over the last two decades, however, there has been an increased focus on the development of antidepressants and antipsychotics on the part of the pharmaceutical industry, clinicians, and researchers, with a reduced interest in BDZs, in spite of their widespread clinical use. As a consequence, many psychiatric residents, medical students, nurses, and other mental health professionals might receive poor academic teaching and training regarding these agents, and have the false impression that BDZs represent an outdated chapter in clinical psychopharmacology. However, recent advances in the field, including findings concerning epidemiology, addiction risk, and drug interactions, as well as the introduction of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition with related diagnostic changes, strongly encourage an updated appraisal of the use of BDZs in clinical practice. During a recent thematic event convened with the aim of approaching this topic in a critical manner, a group of young Italian psychiatrists attempted to highlight possible flaws in current teaching pathways, identify the main clinical pros and cons regarding current use of BDZs in clinical practice, and provide an updated overview of their use across specific clinical areas and patient populations. The main results are presented and discussed in this review.",
keywords = "Benzodiazepines, Psychiatric clinical practice, Risks and benefits, Teaching issues",
author = "Bernardo Dell’Osso and Umberto Albert and Atti, {Anna Rita} and Claudia Carmassi and Giuseppe Carr{\`a} and Fiammetta Cosci and {Del Vecchio}, Valeria and {Di Nicola}, Marco and Silvia Ferrari and Arianna Goracci and Felice Iasevoli and Mario Luciano and Giovanni Martinotti and Nanni, {Maria Giulia} and Alessandra Nivoli and Federica Pinna and Nicola Poloni and Maurizio Pompili and Gaia Sampogna and Ilaria Tarricone and Sarah Tosato and Umberto Volpe and Andrea Fiorillo",
year = "2015",
month = "7",
day = "30",
doi = "10.2147/NDT.S83130",
language = "English",
volume = "11",
pages = "1885--1909",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice

AU - Dell’Osso, Bernardo

AU - Albert, Umberto

AU - Atti, Anna Rita

AU - Carmassi, Claudia

AU - Carrà, Giuseppe

AU - Cosci, Fiammetta

AU - Del Vecchio, Valeria

AU - Di Nicola, Marco

AU - Ferrari, Silvia

AU - Goracci, Arianna

AU - Iasevoli, Felice

AU - Luciano, Mario

AU - Martinotti, Giovanni

AU - Nanni, Maria Giulia

AU - Nivoli, Alessandra

AU - Pinna, Federica

AU - Poloni, Nicola

AU - Pompili, Maurizio

AU - Sampogna, Gaia

AU - Tarricone, Ilaria

AU - Tosato, Sarah

AU - Volpe, Umberto

AU - Fiorillo, Andrea

PY - 2015/7/30

Y1 - 2015/7/30

N2 - More than half a century after their discovery, benzodiazepines (BDZs) still represent one of the largest and most widely prescribed groups of psychotropic compounds, not only in clinical psychiatry but also in the entire medical field. Over the last two decades, however, there has been an increased focus on the development of antidepressants and antipsychotics on the part of the pharmaceutical industry, clinicians, and researchers, with a reduced interest in BDZs, in spite of their widespread clinical use. As a consequence, many psychiatric residents, medical students, nurses, and other mental health professionals might receive poor academic teaching and training regarding these agents, and have the false impression that BDZs represent an outdated chapter in clinical psychopharmacology. However, recent advances in the field, including findings concerning epidemiology, addiction risk, and drug interactions, as well as the introduction of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition with related diagnostic changes, strongly encourage an updated appraisal of the use of BDZs in clinical practice. During a recent thematic event convened with the aim of approaching this topic in a critical manner, a group of young Italian psychiatrists attempted to highlight possible flaws in current teaching pathways, identify the main clinical pros and cons regarding current use of BDZs in clinical practice, and provide an updated overview of their use across specific clinical areas and patient populations. The main results are presented and discussed in this review.

AB - More than half a century after their discovery, benzodiazepines (BDZs) still represent one of the largest and most widely prescribed groups of psychotropic compounds, not only in clinical psychiatry but also in the entire medical field. Over the last two decades, however, there has been an increased focus on the development of antidepressants and antipsychotics on the part of the pharmaceutical industry, clinicians, and researchers, with a reduced interest in BDZs, in spite of their widespread clinical use. As a consequence, many psychiatric residents, medical students, nurses, and other mental health professionals might receive poor academic teaching and training regarding these agents, and have the false impression that BDZs represent an outdated chapter in clinical psychopharmacology. However, recent advances in the field, including findings concerning epidemiology, addiction risk, and drug interactions, as well as the introduction of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition with related diagnostic changes, strongly encourage an updated appraisal of the use of BDZs in clinical practice. During a recent thematic event convened with the aim of approaching this topic in a critical manner, a group of young Italian psychiatrists attempted to highlight possible flaws in current teaching pathways, identify the main clinical pros and cons regarding current use of BDZs in clinical practice, and provide an updated overview of their use across specific clinical areas and patient populations. The main results are presented and discussed in this review.

KW - Benzodiazepines

KW - Psychiatric clinical practice

KW - Risks and benefits

KW - Teaching issues

UR - http://www.scopus.com/inward/record.url?scp=84938861303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938861303&partnerID=8YFLogxK

U2 - 10.2147/NDT.S83130

DO - 10.2147/NDT.S83130

M3 - Article

AN - SCOPUS:84938861303

VL - 11

SP - 1885

EP - 1909

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -